WO2000076541A1 - Pneumococcal surface protein combination vaccine - Google Patents
Pneumococcal surface protein combination vaccine Download PDFInfo
- Publication number
- WO2000076541A1 WO2000076541A1 PCT/US2000/040176 US0040176W WO0076541A1 WO 2000076541 A1 WO2000076541 A1 WO 2000076541A1 US 0040176 W US0040176 W US 0040176W WO 0076541 A1 WO0076541 A1 WO 0076541A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epitope
- pspa
- psaa
- pspc
- pneumococcal
- Prior art date
Links
- 108010052285 Membrane Proteins Proteins 0.000 title claims abstract description 16
- 102000018697 Membrane Proteins Human genes 0.000 title claims abstract description 16
- 229940001442 combination vaccine Drugs 0.000 title description 2
- 230000002163 immunogen Effects 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims description 101
- 108010040473 pneumococcal surface protein A Proteins 0.000 claims description 98
- 239000013598 vector Substances 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 239000002671 adjuvant Substances 0.000 claims description 34
- 230000028993 immune response Effects 0.000 claims description 18
- 208000035109 Pneumococcal Infections Diseases 0.000 claims description 16
- 230000001900 immune effect Effects 0.000 claims description 16
- 230000003053 immunization Effects 0.000 claims description 12
- 102000009016 Cholera Toxin Human genes 0.000 claims description 11
- 108010049048 Cholera Toxin Proteins 0.000 claims description 11
- 229940037003 alum Drugs 0.000 claims description 9
- 230000001681 protective effect Effects 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 229960000856 protein c Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 241000193998 Streptococcus pneumoniae Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 8
- 208000031729 Bacteremia Diseases 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 201000009906 Meningitis Diseases 0.000 description 5
- 206010033078 Otitis media Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- -1 "PspC" Proteins 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001989 nasopharynx Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229940124733 pneumococcal vaccine Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010058859 Pneumococcal bacteraemia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 101710108485 Envelope phospholipase F13 Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027253 Meningitis pneumococcal Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- SUWZHLCNFQWNPE-LATRNWQMSA-N optochin Chemical compound C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 SUWZHLCNFQWNPE-LATRNWQMSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 208000004593 pneumococcal meningitis Diseases 0.000 description 2
- 229940031960 pneumococcal polysaccharide vaccine Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710177917 Fimbrial protein Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001313099 Pieris napi Species 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 101710138270 PspA protein Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000004711 cerebrospinal fluid leak Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229940029584 haemophilus influenzae type b conjugate vaccine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 101150076091 pspC gene Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- Protein C Protein C, "PspC”, and/or Pneumococcal Surface Protein A “PspA”, and/or Pneumococcal Surface Adhesin Protein A, "PsaA” and different clades of PspC and/or PspA and/or PsaA; isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC and/or PspA and or PsaA such as an epitopic region of PspC and/or PspA and/or PsaA; vectors or plasmids which contain and/or express such nucleic acid molecles, e.g., in vitro or in vivo; and immunological, immunogenic or vaccine compositions comprising combinations of at least two of PspC and/or PspA and/or PsaA, and/or a portion thereof (such as epitopic region(s), and/or polypeptide(s) and/or fragment(s) thereof
- the composition can contain an immunogen or immunogens or epitope or epitopes of at least two of PspC and/or PspA and/or PsaA, and/or a vector that so expresses such immunogen(s) or epitope(s).
- the invention further relates to methods of vaccination; and administration, as well as to methods of producing and of formulating these compositions.
- PspC and/or PspA and/or PsaA, or a fragment and/or epitope thereof and thus an immunological, immunogenic or vaccine composition comprising PspC and/or PspA and/or PsaA, or a fragment and/or epitope thereof, or a vector that so expresses such immunogen(s) or epitope(s), can be administered by the same routes, and in approximately the same amounts, as for PspA or PspC, which have been described.
- the invention further provides methods for administering combinations of at least two of PspC and/or PspA and/or PsaA, or a fragment and/or epitope thereof; immunological, immunogenic or vaccine compositions comprising at least two of PspC and/or PspA and/or PsaA, or a fragment and/or epitope thereof, or a vector that so expresses such immunogen(s) or epitope(s); as well as uses of PspC and/or PspA and/or PsaA, or a fragment or/and epitope thereof, or a vector that so expresses such immunogen(s) or epitope(s) to formulate such compositions.
- S. pneumoniae is an important cause of otitis media, meningitis, bacteremia and pneumonia, and a leading cause of fatal infections in the elderly and persons with underlying medical conditions, such as pulmonary disease, liver disease, alcoholism, sickle cell, cerebrospinal fluid leaks, acquired immune deficiency syndrome (AIDS), and patients undergoing immunosuppressive therapy. It is also a leading cause of morbidity in young children.
- Pneumococcal infections cause approximately 40,000 deaths in the U.S. yearly. The most severe pneumococcal infections involve invasive meningitis and bacteremia infections, of which there are 3,000 and 50,000 cases annually, respectively.
- Pneumococci first colonize the upper airways and can remain in nasal mucosa for weeks or months. As many as 50% or more of young children and the elderly are colonized. In most cases, this colonization results in no apparent infection (10-12). Studies of outbreak strains have suggested that even highly virulent strains can colonize without causing disease (13-16). In some individuals, however, the organism carried in the nasopharynx can give rise to symptomatic sinusitis or middle ear infections. If pneumococci are aspirated into the lung, especially with food particles or mucus, they can cause pneumonia. Infections at these sites generally shed some pneumococci into the blood, where they can lead to sepsis, especially if they continue to be shed in large numbers from the original focus of infection.
- Pneumococci in the blood can reach the brain where they can cause meningitis.
- pneumococcal meningitis is less common than other infections caused by these bacteria it is particularly devastating; some 10% of such patients die and greater than 50% of the remainder have life-long neurological sequelae (17-18).
- Pneumococcus asymptomatically colonizes the upper respiratory tract of normal individuals; disease often results from the spread of organisms from the nasopharynx to other tissues during opportunistic events.
- the incidence of carriage in humans varies with age and circumstances. Carrier rates in children are typically higher than are those of adults. Studies have demonstrated that 38 to 60% of preschool children, 29 to 35% of grammar school children and 9 to 25% of junior high school children are carriers of pneumococcus. Among adults, the rate of carriage drops to 6% for those without children at home and to 18 to 29% for those with children at home. It is not surprising that the higher rate of carnage in children than in adults parallels the incidence of pneumococcal disease in these populations.
- Pneumococcal vaccines have been developed by combining the 23 different capsular polysaccharides which are representative of the prevalent types of human pneumococcal disease. These 23 polysaccharide types have been used in a licensed pneumococcal vaccine since 1983
- the licensed 23-valent polysaccharide vaccine has a reported efficacy of approximately 60% in preventing bacteremia caused vaccine type pneumococci in healthy adults.
- the efficacy of the vaccine has been controversial, and at times, the justification for the recommended use of the vaccine questioned. It has been speculated that the efficacy of this vaccine is negatively affected by having to combine 23 different immunogens. Having a large number of immunogens combined in a single formulation may negatively affect the antibody responses to individual types within this mixture because of immunogenic competition.
- the efficacy is also affected by the fact that the 23 serotypes encompass all serological types associated with human infections and carriage. Also, it is not effective in children less than 2 years of age because of their inability to make adequate responses to most polysaccharides (21,22).
- pneumococcal protein immunogens capable of eliciting protective immune responses.
- pneumococcal protein immunogens are Pneumococcal Surface Protein C (PspC), Pneumococcal Surface Protein A (PspA) and Pneumococcal Surface Adhesin Protein A (PsaA).
- PspC Pneumococcal Surface Protein C
- PspA Pneumococcal Surface Protein A
- PsaA Pneumococcal Surface Adhesin Protein A
- Such proteins may serve as vaccines by themselves, or advantageously, as described herein, may be used in combination to produce an enhanced immune response.
- PspA has been identified as a virulence factor and protective immunogen.
- PspA is a cell surface molecule that is found on all clinical isolates, and the expression of PspA is required for the full virulence of pneumococci in mouse (34).
- the biological function of PspA has not been well defined, although a preliminary report suggests that it may inhibit complement activation (27).
- the PspA protein type is independent of capsular type. It would seem that genetic mutation or exchange in the environment has allowed for the development of a large pool of strains which are highly diverse with respect to capsule, PspA, and possibly other molecules with variable structures. Variability of PspA's from different strains also is evident in their molecular weights, which range from 67 to 99 kD. The observed differences are stably inherited and are not the result of protein degradation.
- U.S. Patents and patent applications including U.S. application Serial No. 08/529,055, filed September 15, 1995; U.S. application Serial No.
- PspA is a highly variable surface protein, sufficient homologies have been identified to allow for the grouping of pneumococcal isolates into discrete sets of families or clades. Based on this information, the teachings of which are found in U.S. Patent No. 5,955,089, a combination of 4 to 6 different PspA molecules can be used to engender an immunological response to any given pneumococcal strain.
- PspC and pspC are incorporated herein by reference.
- PspC epitopic regions of PspC, DNA encoding epitopic regions of PspC, and immunological, immunogenic or vaccine compositions comprising at least one PspC are provided in PCT application No. PCT/US99/08895, publication No. WO 99/53940, claiming priority to U.S. provisional application Serial No. 60/082,728, filed April 23, 1998, and U.S. application Serial No. 09/298,523, filed April 23, 1999.
- the teachings of these applications are relevant to the present invention and these applications, together with any and all of the references cited therein, are incorporated herein by reference.
- pneumococcal fimbrial protein A Another pneumococcal surface protein of interest is PsaA.
- Russell et ⁇ l. described an immunogenic, species-common protein from S. pnueumoni ⁇ e designated pneumococcal fimbrial protein A (41).
- This 37 kDa protein immunogen is also described in U.S. Patent No. 5,422,427, the teachings of which are hereby incorporated in their entirety herein by reference.
- the 37 kDa protein which was previously referred to as pneumococcal fimbral protein A, has more recently been designated pneumococcal surface adhesin protein A (PsaA).
- references made to PsaA, pneumococcal surface adhesin protein A, pnuemococcal fimbral protein A, or the 37 kDa immunogen shall all be understood to refer to that certain protein immunogen from S. pneumoniae characterized by Russell et al. (1990) and described in U.S. Patent No. 5,422,427.
- PsaA is common to all 23 pneumococcal vaccine serotypes (41).
- the gene encoding PsaA has been cloned and sequenced (46). More recently, the PsaA gene was cloned from encapsulated strain 6B, and is the subject of pending U.S. application Serial No. 08/222,179. This gene is more representative of clinically relevant strains.
- a recombinant lipidated PsaA protein suitable for use in development of PsaA-based vaccines is described in pending U. S. application Serial
- S pneumoniae In order to establish an infection, S pneumoniae must first gain entry to the host through mucosal surfaces.
- the principal determinant of specific immunity at mucosal surfaces is secretory IgA (S-IgA) which is physiologically and functionally separate from the components of the circulatory immune system.
- S-IgA secretory IgA
- Mucosal S-IgA responses are predominantly generated by the common mucosal immune system
- CMIS cancer-derived lymphoepithelial structures
- MALT mucosa associated lymphoid tissue
- common mucosal immune system refers to the fact that immunization at any mucosal site can elicit an immune response at all other mucosal sites. Thus, immunization in the gut can elicit mucosal immunity in the upper airways and vice versa.
- oral immunization can induce an immunogen-specific IgG response in the systemic compartment in addition to mucosal IgA antibodies (62).
- the reservoir of S. pneumoniae in the world is maintained by nasopharyngeal carriage within human populations. Acquisition of pneumococci is invariably from carriers. Most people carry pneumococci many times during their lives and in the vast majority of cases carriage does not lead to disease. In a minority of cases pneumococci invade from the nasopharynx into the deeper tissue leading to pneumonia, bacteremia, sepsis, and meningitis. Even the frequency of invasion is low per carriage event, the high prevalence of carriage (between 5 and 40% of individuals) means that the morbidity and mortality attributed to S. pneumoniae is very high. In this country, there are over 40,000 deaths due to pneumococcal pneumonia each year.
- Mucosal immunity to PspA has been shown in published studies to be able to reduce and sometimes eliminate carriage of S. pneumoniae in the nasopharynx. More recently it has been demonstrated that immunity to PsaA can also elicit protection against carriage. However, neither protein alone is capable of reproducibly eliciting complete protection against pneumococcal carriage. Thus, a need exists for immunogenic compositions that are capable of reducing pneumococcal carriage. Native protein immunogens such as PspC, PspA, and PsaA, or immunogenic fragments or epitopes thereof, stimulate an immune response when administered to a host.
- Native protein immunogens such as PspC, PspA, and PsaA, or immunogenic fragments or epitopes thereof, stimulate an immune response when administered to a host.
- Recombinant proteins are promising vaccine or immunogenic composition candidates because they can be produced at high yield and purity and manipulated to maximize desirable activities and minimize undesirable ones.
- methods to enhance the immune response to recombinant proteins are important in the development of vaccines or immunogenic compositions.
- Such immunogens especially when recombinantly produced, may elicit a stronger response when administered in conjunction with an adjuvant.
- An adjuvant is a substance that enhances the immunogenicity of an immunogen.
- Adjuvants may act by retaining the immunogen locally near the site of administration to produce a depot effect, facilitating a slow, sustained release of immunogen to cells of the immune system.
- Adjuvants can also attract cells of the immune system, and may attract immune cells to an immunogen depot and stimulate such cells to elicit an immune response.
- Immunostimulating agents or adjuvants have been used for many years to improve the host immune response to, for example, vaccines.
- Intrinsic adjuvants such as lipopolysaccharides, normally are components of the killed or attenuated bacteria used as vaccines.
- Extrinsic adjuvants are immunomodulators that are typically non-covalently linked to immunogens and are formulated to enhance the host immune response.
- Aluminum hydroxide and aluminum phosphate are routinely used as adjuvants in human and veterinary vaccines.
- alum is the only adjuvant licensed for human use, although hundreds of experimental adjuvants such as cholera toxin B are being tested.
- Alternative vaccination strategies are desirable as such provide alternative immunological, immunogenic or vaccine compositions, as well as alternative routes to administration or alternative routes to responses. It would be advantageous to provide an immunological composition or vaccination regimen which elicits protection against various diversified pneumococcal strains, without having to combine a large number of possibly competitive immunogens within the same formulation. And, it is advantageous to provide additional immunogens and epitopes for use in immunological, immunogenic and/or vaccine compositions, e.g., to provide alternative compositions containing or comprising such immunogens or epitopes either alone or in combination with different immunogens.
- An object of the present invention can include providing one or more of: epitopic regions of Pneumococcal Surface Protein C, "PspC”, and/or Pneumococcal Surface Protein A “PspA”, and/or Pneumococcal Surface Adhesin Protein A, "PsaA” and different clades of PspC and/or PspA and/or PsaA; isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC and/or PspA and/or PsaA such as an epitopic region of PspC and/or PspA and/or PsaA; vectors or plasmids which contain and/or express such nucleic acid molecules, e.g., in vitro or in vivo; and immunological, immunogenic or vaccine compositions comprising combinations of at least two of PspC and/or PspA and/or Ps
- the composition can contain an immunogen or immunogens or epitope or epitopes of at least two of PspC and/or PspA and/or PsaA, and/or a vector that so expresses such immunogen(s) or epitope(s).
- the invention further relates to methods of vaccination; and administration, as well as to methods of producing and of formulating these compositions.
- the invention provides a composition comprising: (i) PsaA or an epitope thereof, or a vector that expresses PsaA or an epitope thereof, and (ii) (a) PspA or an epitope thereof or a vector that expresses PspA or an epitope thereof, or (b) PspC or an epitope thereof or a vector that expresses PspC or an epitope thereof, or (c) PspA or an epitope thereof and PspC or an epitope thereof, or a vector that expresses PspA or an epitope thereof and PspC or an epitope thereof, or a first vector that expresses PspA or an epitope thereof and a second vector that expresses PspC or an epitope thereof, or (iii) a vector that expresses PsaA or an epitope thereof and PspA or an epitope thereof and/or PspC or an epitope
- the composition can include a carrier and/or diluents.
- the composition can further comprise an adjuvant.
- the adjuvant can be alum, e.g., aluminum phosphate and/or aluminum hydroxide, for instance, as a gel, Sponin, Quil A, and the water-in-oil adjuvant, Freund's with killed tubercle bacilli (Freund's complete) or without bacilli (Freund's incomplete); see also PCT/US98/23472 with respect to adjuvants that can be used in the practice of this invention.
- compositions e.g., combinations of at least two of PspC and/or PspA and/or PsaA, or a fragment and/or epitope thereof; immunological, immunogenic or vaccine compositions comprising at least two of PspC and/or PspA and/or PsaA, or a fragment and/or epitope(s) thereof, or a vector that so expresses such immunogen(s) or epitope(s); as well as uses of PspC and/or PspA and/or PsaA, or a fragment or/and epitope thereof, or a vector that so expresses such immunogen(s) or epitope(s) to formulate such compositions.
- recombinantly produced PspA and PsaA are formulated together with an adjuvant, such as the B subunit of Cholera toxin B (CTB) or alum.
- CTB and alum function as an adjuvant.
- the PspA and/or PsaA and or PspC combination, together with an adjuvant such as CTB and/or alum, are preferably administered intranasally.
- compositions cited in this disclosure provide typical additional ingredients for such compositions, such that undue experimentation is not required by the skilled artisan to formulate a composition from this disclosure.
- Such compositions should preferably contain quantities of the pneumococcal PspA and/or PsaA and/or PspC or epitopes thereof or vector(s) that so express the protein(s) sufficient to elicit a suitable response. Determination of the optimal amounts of each protein to use in the combination can be determined empirically, with a minimum of experimentation. Those skilled in the art will recognize, for example, that such determination can be based upon amounts of immunogen administered to experimental animals in the examples below and in the documents cited herein.
- the terms “comprising”, “comprises”, “comprises of and the like have the meaning ascribed to these terms under U.S. law and can mean “including”, “includes” and the like.
- the present invention provides an immunological, immunogenic or vaccine composition
- an immunological, immunogenic or vaccine composition comprising combinations of at least two of PspC and/or PspA and/or PsaA, and/or a portion thereof (such as epitopic region(s), and/or polypeptide(s) and/or fragment(s) thereof, of at least two of PspC and/or PspA and/or PsaA) e.g. PsaA (or a fragment thereof) and PspA (or a fragment thereof) and/or PspC (or a fragment thereof) and/or vector or vectors expressing such combinations and a pharmaceutically acceptable carrier or diluent.
- the invention provides a composition comprising: (i) PsaA or an epitope thereof, or a vector that expresses PsaA or an epitope thereof, and (ii) (a) PspA or an epitope thereof or a vector that expresses PspA or an epitope thereof, or (b) PspC or an epitope thereof or a vector that expresses PspC or an epitope thereof, or (c) PspA or an epitope thereof and PspC or an epitope thereof, or a vector that expresses PspA or an epitope thereof and PspC or an epitope thereof, or a first vector that expresses PspA or an epitope thereof and a second vector that expresses PspC or an epitope thereof, or (iii) a vector that expresses PsaA or an epitope thereof and PspA or an epitope thereof and/or PspC or an epitope
- the composition can include a carrier and/or diluents.
- the composition can further comprise an adjuvant.
- An immunological composition elicits an immunological response - local or systemic. The response can, but need not be, protective.
- An immunogenic composition containing the pneumococcal protein combination likewise elicits a local or systemic immunological response which can, but need not be, protective.
- a vaccine composition elicits a local or systemic protective response. Accordingly, the terms "immunological composition” and “immunogenic composition” include a "vaccine composition" (as the two former terms can be protective compositions).
- An epitope of interest is an immunologically relevant region of an immunogen or immunologically active fragment thereof, e.g., from a pathogen or toxin of veterinary or human interest.
- One skilled in the art can determine an epitope or immunodominant region of a peptide or polypeptide and ergo the coding DNA therefor from the knowledge of the amino acid and corresponding DNA sequences of the peptide or polypeptide, as well as from the nature of particular amino acids (e.g., size, charge, etc.) and the codon dictionary, without undue experimentation.
- the DNA sequence preferably encodes at least regions of the peptide that generate an antibody response or a T cell response.
- One method to determine T and B cell epitopes involves epitope mapping.
- the protein of interest is synthetized in short overlapping peptides (PEPSCAN).
- PEPSCAN short overlapping peptides
- the individual peptides are then tested for their ability to bind to an antibody elicited by the native protein or to induce T cell or B cell activation. Janis Kuby, Immunology, (1992) pp.79-80.
- Another method for determining an epitope of interest is to choose the regions of the protein that are hydrophilic. Hydrophilic residues are often on the surface of the protein and are therefore often the regions of the protein which are accessible to the antibody. Janis Kuby, Immunology, (1992) p. 81.
- Still another method for choosing an epitope of interest which can generate a T cell response is to identify from the protein sequence potential HLA anchor binding motifs which are peptide sequences which are known to be likely to bind to the MHC molecule.
- the peptide which is a putative epitope of interest, to generate a T cell response should be presented in a MHC complex.
- the peptide preferably contains appropriate anchor motifs for binding to the MHC molecules, and should bind with high enough affinity to generate an immune response.
- Peptide length the peptide should be at least 8 or 9 amino acids long to fit into the MHC class I complex and at least 13-25 amino acids long to fit into a class II MHC complex. This length is a minimum for the peptide to bind to the MHC complex. It is preferred for the peptides to be longer than these lengths because cells may cut the expressed peptides.
- the peptide should contain an appropriate anchor motif which will enable it to bind to the various class I or class II molecules with high enough specificity to generate an immune response (See Bocchia, M.
- Another method is simply to generate or express portions of a protein of interest, generate monoclonal antibodies to those portions of the protein of interest, and then ascertain whether those antibodies inhibit growth in vitro of the pathogen from which the from which the protein was derived.
- the skilled artisan can use the other guidelines set forth in this disclosure and in the art for generating or expressing portions of a protein of interest for analysis as to whether antibodies thereto inhibit growth in vitro.
- the invention therefore also provides a method of inducing an immunological response in a host mammal comprising administering to the host an inventive immunogenic, immunological or vaccine composition, e.g., a composition comprising a combination of pneumococcal proteins or immunogens, PspC and/or PspA and/or PsaA, or an epitope or fragment thereof, and/or vector or vectors expressing such combinations and a pharmaceutically acceptable carrier or diluent.
- the composition can further comprise an adjuvant and the method can further include administering an adjuvant.
- the combination of PspA and PsaA is synergistic, and results in an improved immunological response and reduced carriage of pneumococci compared to immunization with either immunogens alone.
- each pneumococcal protein or immunogen e.g. PspA and/or PsaA and/or PspC
- optional additional adjuvant in the inventive compositions and the preparation of those compositions can be in accordance with standard techniques well known to those skilled in the pharmaceutical or veterinary arts.
- the amount of immunogen and adjuvant in the inventive compositions and the dosages administered are determined by techniques well known to those skilled in the medical or veterinary arts taking into consideration such factors as the particular immunogengen, the adjuvant (if present), the age, sex, weight, species and condition of the particular animal or patient, and the route of administration.
- dosages of particular PspA and/or PsaA and/or PspC immunogens for suitable hosts in which an immunological response is desired can be readily ascertained by those skilled in the art from this disclosure, as is the amount of any adjuvant typically administered therewith.
- an adjuvant is commonly used as 0.001 to 50 wt% solution in phosphate buffered saline, and the immunogen is present on the order of micrograms to milligrams, such as about 0.0001 to about 5 wt%, preferably about 0.0001 to about 1 wt%, most preferably about
- the immunogen is present in an amount on the order of micrograms to milligrams, or, about 0.001 to about 20 wt%, preferably about 0.01 to about 10 wt%, and most preferably about 0.05 to about 5 wt%.
- any composition to be administered to an animal or human including the components thereof, and for any particular method of administration, it is preferred to determine therefor: toxicity, such as by determining the lethal dose (LD) and LD50 in a suitable animal model e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable immunological response, such as by titrations of sera and analysis thereof for antibodies or immunogens, e.g., by ELISA analysis.
- LD lethal dose
- LD50 low-dil dose
- a suitable immunological response such as by titrations of sera and analysis thereof for antibodies or immunogens, e.g., by ELISA analysis.
- Such determinations do not require undue experimentation from the knowledge of the skilled artisan, this disclosure and the documents cited herein. And, the time for sequential administrations can be ascertained without undue experimentation.
- compositions of the invention include liquid preparations for orifice, e.g., oral, nasal, anal, vaginal, perioral, intragastric, mucosal (e.g., perlingual, alveolar, gingival, olfactory or respiratory mucosa) etc., administration such as suspensions, syrups or elixirs; and, preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration), such as sterile suspensions or emulsions.
- Such compositions may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like.
- the compositions can also be lyophilized.
- compositions can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired.
- Standard texts such as "REMINGTON'S PHARMACEUTICAL SCIENCE", 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.
- compositions of the invention are conveniently provided as liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions or viscous compositions which may be buffered to a selected pH. If digestive tract absorption is preferred, compositions of the invention can be in the "solid" form of pills, tablets, capsules, caplets and the like, including “solid” preparations which are time-released or which have a liquid filling, e.g., gelatin covered liquid, whereby the gelatin is dissolved in the stomach for delivery to the gut. If nasal or respiratory (mucosal) administration is desired, compositions may be in a form and dispensed by a squeeze spray dispenser, pump dispenser or aerosol dispenser.
- Aerosols are usually under pressure by means of a hydrocarbon.
- Pump dispensers can preferably dispense a metered dose or a dose having a particular particle size.
- Compositions of the invention can contain pharmaceutically acceptable flavors and/or colors for rendering them more appealing, especially if they are administered orally.
- the viscous compositions may be in the form of gels, lotions, ointments, creams and the like and will typically contain a sufficient amount of a thickening agent so that the viscosity is from about 2500 to 6500 cps, although more viscous compositions, even up to 10,000 cps may be employed. Viscous compositions have a viscosity preferably of 2500 to
- compositions can approach solid or gelatin forms which are then easily administered as a swallowed pill for oral ingestion.
- Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by injection or orally, to animals, children, particularly small children, and others who may have difficulty swallowing a pill, tablet, capsule or the like, or in multi-dose situations.
- Viscous compositions can be formulated within the appropriate viscosity range to provide longer contact periods with mucosa, such as the lining of the stomach or nasal mucosa.
- suitable carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form, e.g., liquid dosage form (e.g., whether the composition is to be formulated into a solution, a suspension, gel or another liquid form), or solid dosage form (e.g., whether the composition is to be formulated into a pill, tablet, capsule, caplet, time release form or liquid-filled form).
- liquid dosage form e.g., whether the composition is to be formulated into a solution, a suspension, gel or another liquid form
- solid dosage form e.g., whether the composition is to be formulated into a pill, tablet, capsule, caplet, time release form or liquid-filled form.
- Solutions, suspensions and gels normally contain a major amount of water (preferably purified water) in addition to the immunogen, and optional adjuvant.
- compositions can be isotonic, i.e., it can have the same osmotic pressure as blood and lacrimal fluid.
- compositions of this invention may be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes.
- sodium chloride is preferred particularly for buffers containing sodium ions.
- Viscosity of the compositions may be maintained at the selected level using a pharmaceutically acceptable thickening agent.
- Methylcellulose is preferred because it is readily and economically available and is easy to work with.
- suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The preferred concentration of the thickener will depend upon the agent selected. The important point is to use an amount that will achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.
- a pharmaceutically acceptable preservative can be employed to increase the shelf- life of the compositions.
- Benzyl alcohol may be suitable, although a variety of preservatives including, for example, parabens, thimerosal, chlorobutanol, or benzalkonium chloride may also be employed.
- a suitable concentration of the preservative will be from 0.02% to 2% based on the total weight although there may be appreciable variation depending upon the agent selected.
- compositions must be selected to be chemically inert with respect to the pneumococcal immunogens and optional additional adjuvant. This will present no problem to those skilled in chemical and pharmaceutical principles, or problems can be readily avoided by reference to standard texts or by simple experiments (not involving undue experimentation), from this disclosure and the documents cited herein.
- compositions of this invention are prepared by mixing the ingredients following generally accepted procedures.
- the selected components may be simply mixed in a blender, or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.
- the pH may be from about 3 to 7.5.
- Compositions can be administered in dosages and by techniques well known to those skilled in the medical and veterinary arts taking into consideration such factors as the age, sex, weight, and condition of the particular patient or animal, and the composition form used for administration (e.g., solid vs. liquid).
- Dosages for humans or other mammals can be determined without undue experimentation by the skilled artisan, from this disclosure, the documents cited herein, the Examples below (e.g., from the Examples involving mice and from the applications cited herein, e.g., under "Related Applications", especially since administion can be in a manner and dose analogous to PspA or PspC).
- Suitable regimes for initial administration and booster doses or for sequential administrations also are variable, may include an initial administration followed by subsequent administrations; but nonetheless, may be ascertained by the skilled artisan, from this disclosure, the documents cited herein, including applications cited herein, and the Examples below.
- compositions can be administered alone, or can be co- administered or sequentially administered with other compositions of the invention or with other prophylactic or therapeutic compositions.
- concentrations known for PspA or PspC can readily adjust concentrations known for PspA or PspC to account for a combination of at least two of PspC and/or PspA and/or PsaA, or an epitope or fragment thereof.
- the PspC immunogen PspC or an epitope or fragment thereof
- PspA immunogen PspA or an epitope or fragment thereof
- PsaA immunogen PsaA or an epitope or fragment thereof
- the methods for making and/or administering a vector or recombinant or plasmid for expression of PspC and/or PspA and/or PsaA, or a epitope or fragment thereof, either in vivo or in vitro can be any desired method, e.g., a method which is by or analogous to the methods disclosed in: U.S. Patent Nos.
- Patent Nos. 5,591,439, 5,552,143 (recombinant adenovirus), Grunhaus et al., 1992,
- Patent No. 4,394,448 (method of inserting DNA into living cells); and McCormick et al., U.S. Patent No. 5,677,178 (use of cytopathic viruses for therapy and prophylaxis of neoplasia).
- the expression product generated by vectors or recombinants in this invention optionally can also be isolated and/or purified from infected or transfected cells; for instance, to prepare compositions for administration to patients.
- An inventive vector or recombinant expressing PspC, or an epitope or fragment thereof, and/or PspA, or an epitope or fragment thereof and/or PsaA, or an epitope or fragment thereof can be administered in any suitable amount to achieve expression at a suitable dosage level, e.g., a dosage level analogous to the aforementioned dosage levels (wherein the immunogen or epitope of interest is directly present).
- the inventive vector or recombinant can be administered to a patient or infected or transfected into cells in an amount of about at least 10 3 pfu; more preferably about 10 4 pfu to about 10 10 pfu, e.g., about 10 5 pfu to about 10 9 pfu, for instance about 10 6 pfu to about 10 8 pfu.
- the dosage should be a sufficient amount of plasmid to elicit a response analogous to compositions wherein PspC, or an epitope or fragment thereof, and/or PspA, or an epitope or fragment thereof and/or PsaA, or an epitope or fragment thereof are directly present; or to have expression analogous to dosages in such compositions; or to have expression analogous to expression obtained in vivo by recombinant compositions.
- suitable quantities of plasmid DNA in plasmid compositions can be 1 wg to 100 mg, preferably 0.1 to 10 mg, e.g., 500 micrograms, but lower levels such as 0.1 to 2 mg or preferably 1-10 «g may be employed.
- Documents cited herein regarding DNA plasmid vectors may be consulted for the skilled artisan to ascertain other suitable dosages for DNA plasmid vector compositions of the invention, without undue experimentation.
- This Example illustrates the use of a mouse model for pneumococcal carriage.
- Three different strains S. pneumoniae (L82016, BG9163 and BG8826) were inoculated in 12 ⁇ l volumes into the nares of CBA mice over a period of several minutes using slow delivery from a 20 ⁇ l micropipette. After 7 days, the mice were sacrificed and their trachea was cut at the top of the throat. 50 ⁇ l of fluid was instilled and washed out through the nares. The area washed represents the pharynx and nasal tissues. Each of these strains was able to establish carriage in this tissue without concomitant sepsis or bacteremia. The results are shown in Table 1 below. TABLE 1 :
- mice were inoculated with the indicated numbers of CFU i.n. and sacrificed 8 days later. Data expressed as CFU in the 50 ⁇ l nasal wash, in the 1 ml of lung homogenate, or in 50 ⁇ l of blood. Infection of CBA/N mice i.p. with 10 7 L82016 is invariably fatal.
- PspA and PsaA genes were cloned from strain the Rxl/D39 family of strains and the proteins were expressed in E. coli. Mice were immunized with rPspA (pUAB055), PsaA (lot 11.12.98), a combination of both or neither. Both proteins were administered separately or mixed together as 500ng doses in 10 microliter volumes of lactated Ringer's solution. Mice were immunized every Monday and Friday for three consecutive weeks.
- Example 3 The experiment was performed exactly as for Example 1, above, except that the challenge consisted of 1,000,000 colony forming units of C 134, a capsular type 23 S strain of S. pneumoniae. The results are shown in Table 3 below. TABLE 3:
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001502874A JP2003519089A (en) | 1999-06-10 | 2000-06-09 | Pneumococcal surface protein-containing vaccine |
BR0011478-2A BR0011478A (en) | 1999-06-10 | 2000-06-09 | Immune combination composition, methods of inducing an immune response in an animal, and of immunizing a host against pneumococcal infection, and immunogenic composition for intranasal administration |
EP00947640A EP1189632A4 (en) | 1999-06-10 | 2000-06-09 | Pneumococcal surface protein combination vaccine |
CA002379327A CA2379327A1 (en) | 1999-06-10 | 2000-06-09 | Pneumococcal surface protein combination vaccine |
AU61210/00A AU6121000A (en) | 1999-06-10 | 2000-06-09 | Pneumococcal surface protein combination vaccine |
MXPA01012721A MXPA01012721A (en) | 1999-06-10 | 2000-06-09 | Pneumococcal surface protein combination vaccine. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13842299P | 1999-06-10 | 1999-06-10 | |
US60/138,422 | 1999-06-10 | ||
US58783300A | 2000-06-06 | 2000-06-06 | |
US09/587,833 | 2000-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000076541A1 true WO2000076541A1 (en) | 2000-12-21 |
Family
ID=26836182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/040176 WO2000076541A1 (en) | 1999-06-10 | 2000-06-09 | Pneumococcal surface protein combination vaccine |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1189632A4 (en) |
JP (1) | JP2003519089A (en) |
AU (1) | AU6121000A (en) |
BR (1) | BR0011478A (en) |
CA (1) | CA2379327A1 (en) |
MX (1) | MXPA01012721A (en) |
WO (1) | WO2000076541A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022168A2 (en) * | 2000-09-15 | 2002-03-21 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
EP1625393A2 (en) * | 2003-05-16 | 2006-02-15 | Erasmus Universitair Medisch Centrum | Method for selecting and producing vaccine components and vaccines based thereon |
US7078042B2 (en) * | 1995-09-15 | 2006-07-18 | Uab Research Foundation | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
WO2008022298A2 (en) * | 2006-08-17 | 2008-02-21 | The Uab Research Foundation | Immunogenic pcpa polypeptides and uses thereof |
EP2863944A4 (en) * | 2012-06-22 | 2016-05-11 | Epitope Ltd Epitode Ltd | Chimeric protein vaccine against pneumonia caused by streptococcus pneumoniae |
CN105764918A (en) * | 2013-10-14 | 2016-07-13 | 爱丁堡大学董事会 | Proteins with diagnostic and therapeutic uses |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101627285B1 (en) * | 2014-06-05 | 2016-06-07 | 한국생명공학연구원 | A pharmeceutical composition for preventing or treating degenerative brain disease comprising PspA, as active ingredient |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5854416A (en) * | 1991-11-14 | 1998-12-29 | The United States Of America As Represented By The Department Of Health And Human Services | Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor |
WO1999045121A1 (en) * | 1998-03-02 | 1999-09-10 | The Government Of The United States Of America, Represented By The Secretary Of The Department Health And Human Services | EPITOPE PEPTIDES IMMUNOGENIC AGAINST $i(STREPTOCOCCUS PNEUMONIAE) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014318A1 (en) * | 1992-12-24 | 1994-07-07 | Medimmune, Inc. | Method of protection against streptococcus pneumoniae with transformed mycobacteria |
EP1073450A4 (en) * | 1998-04-23 | 2003-04-23 | Uab Research Foundation | PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR |
-
2000
- 2000-06-09 AU AU61210/00A patent/AU6121000A/en not_active Abandoned
- 2000-06-09 CA CA002379327A patent/CA2379327A1/en not_active Abandoned
- 2000-06-09 WO PCT/US2000/040176 patent/WO2000076541A1/en not_active Application Discontinuation
- 2000-06-09 MX MXPA01012721A patent/MXPA01012721A/en unknown
- 2000-06-09 EP EP00947640A patent/EP1189632A4/en not_active Withdrawn
- 2000-06-09 JP JP2001502874A patent/JP2003519089A/en active Pending
- 2000-06-09 BR BR0011478-2A patent/BR0011478A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5854416A (en) * | 1991-11-14 | 1998-12-29 | The United States Of America As Represented By The Department Of Health And Human Services | Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor |
WO1999045121A1 (en) * | 1998-03-02 | 1999-09-10 | The Government Of The United States Of America, Represented By The Secretary Of The Department Health And Human Services | EPITOPE PEPTIDES IMMUNOGENIC AGAINST $i(STREPTOCOCCUS PNEUMONIAE) |
Non-Patent Citations (6)
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078042B2 (en) * | 1995-09-15 | 2006-07-18 | Uab Research Foundation | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
EP2305297A1 (en) * | 2000-09-15 | 2011-04-06 | GlaxoSmithKline Biologicals s.a. | Vaccine against streptococcus pneumoniae |
WO2002022168A3 (en) * | 2000-09-15 | 2002-06-27 | Smithkline Beecham Biolog | Vaccine against streptococcus pneumoniae |
EP2305298A1 (en) * | 2000-09-15 | 2011-04-06 | GlaxoSmithKline Biologicals s.a. | Vaccine against streptococcus pneumoniae |
WO2002022168A2 (en) * | 2000-09-15 | 2002-03-21 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
EP2140878A1 (en) * | 2000-09-15 | 2010-01-06 | GlaxoSmithKline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
EP1625393B1 (en) * | 2003-05-16 | 2010-10-13 | Mucosis B.V. | Vaccines conferring protection to infection by Streptococcus pneumonia. |
EP1625393A2 (en) * | 2003-05-16 | 2006-02-15 | Erasmus Universitair Medisch Centrum | Method for selecting and producing vaccine components and vaccines based thereon |
AU2004239596B2 (en) * | 2003-05-16 | 2011-03-03 | Mucosis B.V. | Method for selecting and producing vaccine components and vaccines based thereon |
WO2008022302A2 (en) * | 2006-08-17 | 2008-02-21 | The Uab Research Foundation | Immunogenic pcpa polypeptides and uses thereof |
WO2008022298A3 (en) * | 2006-08-17 | 2008-04-03 | Uab Research Foundation | Immunogenic pcpa polypeptides and uses thereof |
WO2008022302A3 (en) * | 2006-08-17 | 2008-04-03 | Uab Research Foundation | Immunogenic pcpa polypeptides and uses thereof |
AU2007285775B2 (en) * | 2006-08-17 | 2011-03-03 | Sanofi Pasteur Ltd. | Immunogenic PcpA polypeptides and uses thereof |
WO2008022298A2 (en) * | 2006-08-17 | 2008-02-21 | The Uab Research Foundation | Immunogenic pcpa polypeptides and uses thereof |
US8252546B2 (en) | 2006-08-17 | 2012-08-28 | The Uab Research Foundation | Diagnosing pneumococcal pneumonia |
EP2863944A4 (en) * | 2012-06-22 | 2016-05-11 | Epitope Ltd Epitode Ltd | Chimeric protein vaccine against pneumonia caused by streptococcus pneumoniae |
CN105764918A (en) * | 2013-10-14 | 2016-07-13 | 爱丁堡大学董事会 | Proteins with diagnostic and therapeutic uses |
CN105764918B (en) * | 2013-10-14 | 2021-08-27 | 爱丁堡大学董事会 | Proteins with diagnostic and therapeutic uses |
Also Published As
Publication number | Publication date |
---|---|
EP1189632A4 (en) | 2002-08-21 |
CA2379327A1 (en) | 2000-12-21 |
EP1189632A1 (en) | 2002-03-27 |
MXPA01012721A (en) | 2004-10-14 |
BR0011478A (en) | 2002-03-19 |
AU6121000A (en) | 2001-01-02 |
JP2003519089A (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU726927B2 (en) | Strain selection of pneumococcal surface proteins | |
AU770378B2 (en) | Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor | |
US7960535B2 (en) | Recombinant lipidated PsaA protein, methods of preparation and use | |
US6042838A (en) | immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA) | |
WO2009033742A2 (en) | Streptococcus pneumoniae vaccines | |
EP0682950B1 (en) | Mucosal administration of pneumococcal antigens | |
EP1189632A1 (en) | Pneumococcal surface protein combination vaccine | |
US7078042B2 (en) | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor | |
US20120064105A1 (en) | Engineered Type IV Pilin of Clostridium difficile | |
JP2017160238A (en) | Fused antigen vaccine and composition against streptococcus pneumoniae | |
US6232116B1 (en) | Oral administration of pneumococcal antigens | |
US7049419B2 (en) | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor | |
RU2701733C1 (en) | Live vaccine based on enterococcus faecium l3 probiotic strain for prevention of infection caused by streptococcus pneumonie | |
AU709368B2 (en) | Oral administration of pneumococcal antigens | |
ES2382893T3 (en) | BVH-A2 and BVH-3 antigens of group B streptococcus | |
AU734488B2 (en) | Mucosal administration of pneumococcal antigens | |
WO2000076587A1 (en) | Antibody-based treatment for streptococcus pneumoniae infection | |
MXPA00007261A (en) | RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2379327 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2001 502874 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/012721 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 61210/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000947640 Country of ref document: EP Ref document number: 516451 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2000947640 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000947640 Country of ref document: EP |